Document is current
Any future updates will be listed below
-
Authors
Patelli, Giorgio https://orcid.org/0000-0001-8697-2158
Lazzari, Luca https://orcid.org/0000-0001-6841-4240
Crisafulli, Giovanni
Sartore-Bianchi, Andrea https://orcid.org/0000-0003-0780-0409
Bardelli, Alberto
Siena, Salvatore
Marsoni, Silvia https://orcid.org/0000-0002-5361-7122
- License Information
-
More Information
Article History
Received: 10 May 2024
Accepted: 5 April 2025
First Online: 24 April 2025
Competing interests
: A. Bardelli reports receipt of grants/research supports from Neophore, AstraZeneca and Boehringer Ingelheim and honoraria/consultation fees from Guardant Health. A.B. is stock shareholder of Neophore and Kither Biotech. A.B. is advisory boards member for Neophore. S. Siena is an advisory board member for Agenus, AstraZeneca, Bayer, Bristol Meyer Squibb, CheckmAb, Daiichi-Sankyo, GlaxoSmithKline, MSD, Merck, Novartis, Pierre Fabre, Seagen, and T-One Therapeutics. A. Sartore-Bianchi reports personal fees from Amgen, Bayer, Servier, Pierre Fabre, and Takeda during the conduct of the study. A. Sartore-Bianchi is an Editorial Board Member for Communications Medicine, but was not involved in the editorial review or peer review, nor in the decision to publish this article. All other authors declare no competing interests.
